Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

1. Discovery of a Potent Candidate for RET-Specific Non-Small-Cell Lung Cancer-A Combined In Silico and In Vitro Strategy.Pharmaceutics · 2021
   Article
2. [Research Progress of Fusion Genes RET in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2021
   Review
3. Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules.Cell · 2021
   Article
4. RET Gene Fusions in Malignancies of the Thyroid and Other Tissues.Genes · 2020
   Review
5. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.The Journal of biological chemistry · 2019
   Article
6. RET in breast cancer: pathogenic implications and mechanisms of drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2019
   Review

Corrections and comments

• Comment on
  Precision Targeted Therapy with BLU-667 for2018

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as